Application of folate receptor 2 as biomarker of atherosclerotic cardiovascular disease

By using folic acid receptor 2 as a biomarker to detect its gene and protein expression levels, the problem of insufficient specificity and sensitivity in the diagnosis of atherosclerotic cardiovascular disease is solved, and higher diagnostic accuracy and specificity are achieved , provides new diagnostic aids.

CN118932042APending Publication Date: 2024-11-12梅州市人民医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411125325.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, the biomarker specificity and sensitivity of atherosclerotic cardiovascular disease lead to inaccurate diagnosis.

Method used

Using folate receptor 2 (FOLR2) as a novel biomarker, diagnostic reagents and products for atherosclerotic cardiovascular disease were developed by detecting its gene and protein expression levels, combined with bioinformatics analysis and experimental verification.

Benefits of technology

The diagnostic sensitivity and specificity of atherosclerotic cardiovascular disease has been significantly improved, with the AUC value reaching 0.957, providing a more reliable diagnostic basis and condition assessment tool.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932042A_ABST
    Figure CN118932042A_ABST
Patent Text Reader

Abstract

The invention discloses application of a folate receptor 2 as a biomarker of atherosclerotic cardiovascular disease. By integrating a plurality of public data sets closely related to the atherosclerosis pathological process, applying a bioinformatics analysis method and combining experimental verification, the invention finds that the expression of the FOLR2 gene in plaques of atherosclerotic cardiovascular disease patients at different pathological stages is increased, and the FOLR2 gene has high expression in plaques of atherosclerotic cardiovascular disease patients at different pathological stages. And the protein coded by the gene can effectively distinguish and diagnose patients with atherosclerotic cardiovascular diseases and patients with non-atherosclerotic cardiovascular diseases. Therefore, the FOLR2 has the potential of serving as a biomarker of the atherosclerotic cardiovascular disease, and a new auxiliary means is provided for diagnosis of the atherosclerotic cardiovascular disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and more specifically, to a biomarker associated with atherosclerotic cardiovascular disease and its application. Background Art

[0002] Atherosclerotic cardiovascular disease (ASCVD) is a general term for a wide range of atherosclerotic diseases and one of the most common cardiovascular diseases. Its morbidity and mortality have been increasing in my country in recent years. The main cause of ASCVD is atherosclerosis, which not only leads to stenosis or occlusion of the vascular lumen, but also causes serious consequences such as angina pectoris, myocardial infarction and even stroke due to the instability of plaques. ASCVD often includes acute coronary syndrome, stable coronary heart disease, post-revascularization surgery, ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, and peripheral arterial atherosclerosis ("China Cardiovascular Health and Disease Report Writing Group. Summary of China Cardiovascular Health and Disease Report 2019 [J]. Chinese Journal of Circulation, 2020, 35(9): 833-854. DOI: 10.3969 / j.issn.1000-3614.2020.09.001.").

[0003] The occurrence and development of atherosclerosis involves complex biological processes, including lipid deposition, inflammatory response, cell proliferation and apoptosis. In addition, the overactivation of matrix metalloproteinases, reactive oxygen species and proinflammatory cytokines jointly promote the instability and rupture of plaques. At present, the diagnosis of atherosclerotic cardiovascular disease is mainly achieved through imaging techniques, such as ultrasound, CT and MRI. In contrast, biomarker detection has shown great potential in the initial screening, diagnosis and prognosis evaluation of the disease with its advantages of convenience, speed and easy interpretation of results. Current studies have found a variety of biomarkers in patients with atherosclerosis, such as high-sensitivity C-reactive protein, metalloproteinase-9, soluble CD40 ligand and cell adhesion molecules. Although these markers have certain reference value in the diagnosis of atherosclerosis, their specificity and sensitivity are still insufficient. Therefore, more specific and sensitive biomarkers are urgently needed in clinical practice to help accurately diagnose and monitor the condition of patients with atherosclerosis.

[0004] Folate receptor 2 (FOLR2) (also known as folate receptor β) is a member of the folate receptor family and plays an important role in the process of folate uptake. FOLR2 is mainly expressed in the placenta and hematopoietic cells in normal tissues. In various pathological conditions, such as autoimmune diseases, tumors, and unstable atherosclerotic plaques, the expression of FOLR2 on the surface of activated macrophages is significantly upregulated. In particular, in the process of atherosclerosis, local macrophages highly express FOLR2, suggesting that it has extremely high specificity and application prospects as a potential diagnostic marker. However, the current research on the expression level of FOLR2 in the tissues and blood of patients with atherosclerotic cardiovascular disease and its diagnostic efficacy is still insufficient. Summary of the invention

[0005] Based on the above problems, the purpose of the present invention is to provide a new biomarker based on FOLR2, so as to solve the technical problem of insufficient specificity and sensitivity of biomarkers in the current diagnosis of atherosclerotic cardiovascular disease. The biomarker FOLR2 can improve the accuracy and reliability of the diagnosis of atherosclerotic cardiovascular disease, thereby providing clinicians with a more reliable diagnostic basis and disease assessment tool.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The invention discloses application of a reagent for detecting the expression level of folate receptor 2 in a sample in preparing a product for diagnosing atherosclerotic cardiovascular disease.

[0008] Specifically, the present invention proposes a new biomarker FOLR2 for the diagnosis of atherosclerotic cardiovascular disease. The present invention analyzes the expression characteristics of the FOLR2 gene by integrating multiple public data sets closely related to the pathological process of atherosclerosis and using bioinformatics analysis methods, and experimentally verifies the high expression characteristics of the FOLR2 gene in plaque tissue, and the FOLR2 protein level is significantly increased in the serum of patients with atherosclerotic cardiovascular disease. The performance of FOLR2 in the diagnosis of atherosclerotic cardiovascular disease is evaluated by ROC curve analysis. The results show that FOLR2 has high diagnostic accuracy and discrimination, with an AUC value of 0.957, indicating that it has high application value in clinical diagnosis.

[0009] Furthermore, the reagent comprises:

[0010] A reagent for detecting the mRNA expression level of folate receptor 2 in a sample; or,

[0011] A reagent for detecting the protein expression level of folate receptor 2 in a sample.

[0012] Furthermore, the product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the mRNA expression level of folate receptor 2 in a sample from the subject.

[0013] Furthermore, the product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the protein expression level of folate receptor 2 in a sample from the subject.

[0014] Furthermore, the reagents for detecting the mRNA expression level of folate receptor 2 in a sample include reagents required for detecting the mRNA expression level of folate receptor 2 by high-throughput RNA sequencing, RNA-in situ hybridization, digital PCR or fluorescent quantitative PCR method.

[0015] Furthermore, the reagents for detecting the protein expression level of folate receptor 2 in the sample include reagents required for detecting the protein expression level of folate receptor 2 by chemiluminescence, immunofluorescence, protein chip, protein spectrum, immunohistochemistry, plaque tracing based on labeling technology (including but not limited to isotope-labeled antibodies or proteins, fluorescently labeled antibodies or proteins, etc.), western blotting or enzyme-linked immunosorbent assay.

[0016] Furthermore, the sample is a serum, plasma or tissue sample.

[0017] Furthermore, the product is a detection kit.

[0018] Furthermore, the product is a detection chip.

[0019] Furthermore, the product is a test strip.

[0020] The beneficial effects of the present invention are as follows:

[0021] The novel biomarker FOLR2 for diagnosing atherosclerotic cardiovascular disease provided by the present invention has shown significant beneficial effects in improving the sensitivity and specificity of diagnosing atherosclerotic cardiovascular disease. First, through bioinformatics analysis, the present invention found that the FOLR2 gene showed a high expression trend in late plaques, hemorrhagic plaques and atherosclerotic plaques in different parts of the artery, and the experimental verification results further confirmed that its expression in plaque tissue was significantly higher than that in adjacent normal tissue. This discovery provides an important basis for the early identification of atherosclerotic cardiovascular disease and helps to improve the sensitivity of diagnosis. In the biomarker validation stage, it was found that the FOLR2 protein level in the serum of patients with atherosclerotic cardiovascular disease was significantly increased, which proved its sensitivity as a diagnostic indicator. The present invention not only reveals the high expression characteristics of FOLR2 in plaques related to atherosclerotic cardiovascular disease, but also evaluates its specificity as a diagnostic marker through ROC curve analysis. The results showed that the AUC value of FOLR2 was 0.957, indicating that it has a high accuracy in distinguishing patients with atherosclerotic cardiovascular disease from patients with non-atherosclerotic cardiovascular disease, thereby effectively enhancing the specificity of diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings.

[0023] Figure 1 The expression results of FOLR2 gene in the dataset GSE28829 are shown.

[0024] Figure 2 The expression results of FOLR2 gene in the dataset GSE163154 are shown.

[0025] Figure 3 The expression results of FOLR2 gene in the data set GSE43292 are shown.

[0026] Figure 4 The expression results of FOLR2 gene in the data set GSE100927 are shown.

[0027] Figure 5 The figure shows the expression of FOLR2 gene in human carotid artery plaque and its adjacent tissue detected by fluorescence quantitative PCR; the left figure represents human carotid artery dissection tissue (including atherosclerotic plaque area and adjacent tissue without plaque); the right figure represents the fluorescence quantitative PCR detection results of FOLR2 gene between the two groups.

[0028] Figure 6 The results of ELISA technique for measuring the level of FOLR2 protein in peripheral blood serum of patients with atherosclerotic cardiovascular disease and non-atherosclerotic cardiovascular disease are shown.

[0029] Figure 7 The results of the diagnostic performance of peripheral blood serum FOLR2 are shown. DETAILED DESCRIPTION

[0030] In order to more clearly illustrate the present invention, the present invention is further described below in conjunction with preferred embodiments and accompanying drawings. Similar components in the accompanying drawings are represented by the same reference numerals. It should be understood by those skilled in the art that the content specifically described below is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0031] The experimental materials used in the present invention are as follows:

[0032] Reagents and consumables:

[0033] The reagents used in the present invention include: Trizol (Invitrogen), PrimeScript TM RT reagent Kit with gDNA Eraser (Takara), TB Premix Ex TagTMII (Takara), FOLR2 and internal reference gene amplification primers (5'-TGTCTGTATGGATGCCAAGC-3' and 5'-AGGTGTCCTGGATGAAGTGG-3' are used to amplify FLOR2; 5'-CTCCTCCACCTTTGACGC-3' and 5'-CCACCACCCTGTTGCTGT-3' are used to amplify the internal reference gene GAPDH), ELISA kit (Wuhan Fine Biology); the consumables used in the present invention include: pipette tips, enzyme-free EP tubes, PCR eight-tube strips and other consumables.

[0034] Experimental instruments:

[0035] Spectrophotometer (Thermo Fisher), microplate reader (Thermo Fisher), fluorescence quantitative PCR instrument (ABI) and other instruments.

[0036] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0037] The present invention provides a new marker for the diagnosis of atherosclerotic cardiovascular disease, aiming to improve the sensitivity and specificity of the diagnosis of atherosclerotic cardiovascular disease and provide a new auxiliary means for clinical diagnosis. The technical solution is mainly based on bioinformatics analysis and experimental verification, as follows:

[0038] Example 1 Analysis of the expression of FOLR2 gene in atherosclerosis-related datasets

[0039] 1. Dataset acquisition

[0040] Four datasets closely related to the pathological process of atherosclerosis (GSE28829, GSE163154, GSE43292, and GSE100927) were screened from the public database GEO. These datasets cover plaque samples of different pathological stages and types, ensuring the comprehensiveness and depth of subsequent analysis.

[0041] 2. Bioinformatics Analysis

[0042] Target gene selection: The present invention focuses on the FOLR2 gene, and reveals the expression characteristics of the gene in the process of atherosclerosis by extracting and analyzing its expression levels in the expression matrix of each data set.

[0043] Expression pattern exploration:

[0044] In the GSE28829 dataset, the present invention found that the expression level of FOLR2 in advanced plaques was significantly higher than that in early plaques, suggesting its potential role in the progression of plaques ( Figure 1 ). The GSE163154 dataset further showed that the expression level of FOLR2 in hemorrhagic plaques was significantly higher than that in non-hemorrhagic plaques, suggesting that it may be closely related to the stability of the plaque ( Figure 2 ). The GSE43292 dataset confirmed the differential expression pattern of FOLR2 in atherosclerotic plaques and their adjacent tissues, especially the significantly increased expression in atherosclerotic plaques ( Figure 3 ). Cross-site analysis of the GSE100927 dataset showed that FOLR2 showed a consistent high expression trend in carotid artery, femoral artery and lower limb artery plaques, indicating its universality and importance as a marker related to atherosclerotic cardiovascular disease ( Figure 4 ).

[0045] Example 2 Experimental verification of FOLR2 gene expression in patients with carotid artery stenosis

[0046] Sample collection: Samples obtained from 3 patients with carotid artery stenosis by carotid endarterectomy were collected and divided into two parts: carotid plaque and adjacent tissue.

[0047] RNA extraction from human carotid artery dissection tissue: take appropriate amount of tissue, cut into pieces, add liquid nitrogen and grind into powder quickly, transfer to 1mL Trizol EP tube and shake for 2h to fully lyse the tissue; centrifuge the sample at 4℃, 11000g for 10min, transfer the supernatant to a new EP tube with 200μL chloroform, shake vigorously and let stand at room temperature for 3min; centrifuge at 4℃, 11000g for 15min, transfer the colorless aqueous phase (RNA solution) to a new EP tube, add 500μL isopropanol and mix, let stand at room temperature for 10min; centrifuge at 4℃, 11000g for 10min, discard the supernatant and add 75% ethanol; centrifuge at 4℃, 7500g for 5min, discard the supernatant, dry at room temperature for 3-5min, add 25μl enzyme-free water to dissolve the total RNA, and measure the concentration.

[0048] RNA reverse transcription: Add 2μL 5×gDNA Eraser Buffer and 1μL gDNAEraser to a 200μL PCR tube, add 1μg RNA, and finally add enzyme-free water to 10μL. Flick gently, centrifuge slightly, and incubate at 42℃ in a PCR instrument for 2min to remove genomic DNA; add 1μL PrimeScript RT Enzyme Mix I, 1μL RTPrimer Mix, 4μL 5× PrimeScript Buffer 2 (for Real Time) and 4μL enzyme-free water to the above reaction solution. Flick gently, centrifuge slightly, and synthesize cDNA in the PCR instrument according to the following steps: 37℃15min, 85℃5s.

[0049] Fluorescence quantitative PCR detection: add 1 μL cDNA, 1 μL amplification primer, 3 μL enzyme-free water, 5 μL TB into a 200 μL PCR tube. Premix Ex Tag TM II, the reaction was carried out in the PCR instrument in the following steps: pre-denaturation: 95°C, 30s; PCR reaction: 95°C, 5s, 60°C, 34s, and PCR reaction was repeated for 40 cycles. After the fluorescence curve value was generated, the relative expression of the target gene was calculated according to the formula 2^-△△Ct, where △Ct=Ct(target gene)-Ct(reference gene).

[0050] Gene expression detection results: Fluorescence quantitative PCR technology was used to detect the expression level of FOLR2 in carotid artery plaques and adjacent tissues at the mRNA level. Figure 5 The expression level of FOLR2 gene in carotid artery plaque tissue was significantly higher than that in its adjacent tissue, which was highly consistent with the results of bioinformatics analysis.

[0051] Example 3 ELISA method to detect FOLR2 protein levels in the serum of patients with atherosclerotic cardiovascular disease and non-atherosclerotic cardiovascular disease

[0052] Sample collection: In order to verify whether the protein encoded by the FOLR2 gene has the potential to be used as a biomarker, the present invention collected peripheral blood serum samples from 21 patients with atherosclerotic cardiovascular disease and 10 patients with non-atherosclerotic cardiovascular disease. The ELISA technique was used to evaluate the level of FOLR2 protein in the serum.

[0053] Among them, the inclusion criteria for patients with atherosclerotic cardiovascular disease were based on imaging examinations and clinical diagnosis of acute coronary syndrome, stable coronary heart disease, ischemic cardiomyopathy, acute myocardial infarction, ischemic stroke or peripheral atherosclerosis, and patients with concurrent infections, tumors, and autoimmune diseases were excluded.

[0054] ELISA test:

[0055] 1) Sample preparation and dilution: Take an appropriate amount of serum and dilute it with sample diluent at a ratio of 1:3.

[0056] 2) Sample addition: Add 100 μL of standard and diluted serum samples to the corresponding wells and incubate at 37°C for 90 minutes;

[0057] 3) Washing: discard the supernatant and wash the plate twice with 1x washing buffer;

[0058] 4) Add biotin-labeled antibody: add 100 μL of biotin antibody working solution into the wells and incubate at 37°C for 60 minutes;

[0059] 5) Washing: discard the supernatant and wash the plate 3 times with 1x washing buffer;

[0060] 6) Add HRP-streptavidin conjugate (SABC): add 100 μL SABC working solution into the wells and incubate at 37°C for 30 minutes;

[0061] 7) Washing: discard the supernatant and wash the plate 5 times with 1x washing buffer;

[0062] 8) Add TMB substrate: add 90 μL TMB to the wells and incubate at 37°C in the dark for 10-20 minutes;

[0063] 9) Stop reaction: Add 50 μL of stop working solution to each well, measure the OD value at 450 nm using a microplate reader, draw a standard curve and calculate the sample concentration.

[0064] Experimental results: The level of FOLR2 protein in the peripheral blood serum of patients with atherosclerotic cardiovascular disease was significantly higher than that of the non-atherosclerotic cardiovascular disease group. Figure 6 .

[0065] Example 4 Evaluation of the diagnostic efficacy of FOLR2 protein

[0066] Using the receiver operating characteristic curve (ROC) analysis of Example 3, the present invention evaluated the performance of serum FOLR2 protein in the diagnosis of atherosclerotic cardiovascular disease. The ROC curve analysis results show that Figure 7 The AUC value of serum FOLR2 was 0.957, indicating that it has high diagnostic accuracy and discrimination. This result further confirms the potential and value of FOLR2 protein as a new biomarker for the diagnosis of atherosclerotic cardiovascular disease.

[0067] The present invention uses published data sets and experimental verification to find that the expression of the FOLR2 gene is elevated in plaques at different pathological stages, and the protein encoded by the gene can effectively distinguish and diagnose patients with atherosclerotic cardiovascular disease and non-atherosclerotic cardiovascular disease. Therefore, FOLR2 has the potential to be a biomarker for atherosclerotic cardiovascular disease, providing a new auxiliary means for the diagnosis of atherosclerotic cardiovascular disease.

[0068] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not limitations on the implementation methods of the present invention. For ordinary technicians in the relevant field, other different forms of changes or modifications can be made based on the above description. It is impossible to list all the implementation methods here. All obvious changes or modifications derived from the technical solution of the present invention are still within the protection scope of the present invention.

Claims

1. Application of a reagent for detecting the expression level of folate receptor 2 in a sample in the preparation of a product for diagnosing atherosclerotic cardiovascular disease.

2. The use according to claim 1, characterized in that: The reagents include: A reagent for detecting the mRNA expression level of folate receptor 2 in a sample; or, A reagent for detecting the protein expression level of folate receptor 2 in a sample.

3. The use according to claim 1, characterized in that: The product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the mRNA expression level of folate receptor 2 in a sample from the subject.

4. The use according to claim 1, characterized in that: The product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the protein expression level of folate receptor 2 in a sample from the subject.

5. The use according to claim 2, characterized in that: The reagents for detecting the mRNA expression level of folate receptor 2 in a sample include reagents required for detecting the mRNA expression level of folate receptor 2 by high-throughput RNA sequencing, RNA-in situ hybridization, digital PCR or fluorescent quantitative PCR method.

6. The use according to claim 2, characterized in that: Reagents for detecting the protein expression level of folate receptor 2 in a sample include reagents required for detecting the protein expression level of folate receptor 2 by chemiluminescence, immunofluorescence, protein chip, protein spectrum, immunohistochemistry, plaque tracing based on labeling technology, protein blotting or enzyme-linked immunosorbent assay.

7. The use according to claim 1, characterized in that: The sample is a serum, plasma or tissue sample.

8. The use according to claim 1, characterized in that: The product is a detection kit.

9. The use according to claim 1, characterized in that: The product is a detection chip.

10. The use according to claim 1, characterized in that: The product is a test strip.